vialroom

#retatrutide 2026-03-20

Friday15 messages5 participantstimes are UTC
Highlights from this day
  • electrolyte_eli — appetite suppression at 5 was stronger than my tirzepatide experience at a comparable point 18:08
  • ghk_gia — phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan 19:03
  • yyz_vial — TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule 19:31
  • yyz_vial — right so phase 2 was still trending at the end which is why the phase 3 readout matters more than usual, anyway 20:44
  • quiet.hours — Janoshik came back 99 on one lot and 99.4 on the next from the same BCH, both fine 20:48
EE

i went up too fast, got a fortnight of nothing but nausea, and dropped back two steps

appetite suppression at 5 was stronger than my tirzepatide experience at a comparable point

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.
GG

phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan

GG

ok so there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists

YV

sat at 15 for 4 months rather than climbing and it kept working, so i never went up

YV

did the phase 2 plateau or was it still moving at the end

*PeptideMeter not the other one

YV

right so phase 2 was still trending at the end which is why the phase 3 readout matters more than usual, anyway

📉7
QH

low and slow

vial-c-4402-front.png
900 × 1200 · 903 KB · not retained in the public archive
📉1

Janoshik came back 99 on one lot and 99.4 on the next from the same BCH, both fine